← Back to Search

Herbal Supplement

Virtiva Plus for Stress

N/A

Waitlist Available

Research Sponsored by Applied Science & Performance Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Aged 50 to 70 years

Be older than 18 years old

Must not have

History of cardiovascular disease (i.e., myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease, other)

History of neurological disorders (Parkinson's, Amyotrophic lateral sclerosis, epilepsy, spinal cord injury resulting in inability to use upper extremities, other)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre-event, 5 weeks post event

Awards & highlights

No Placebo-Only Group

Summary

This trial will study how Virtiva® Plus affects stress and cognitive performance in people under stress. They will give either a low dose or high dose of Virtiva® Plus to participants and measure any side

Who is the study for?

This trial is for men and women aged 50-70 with a BMI of 18.5-29.99, willing to take Virtiva® Plus twice daily for 5 weeks and avoid diet changes or other cognitive supplements during the study. Participants must understand English, consent in writing, and follow the study schedule.

What is being tested?

The trial tests low (240 mg/day) versus high (480 mg/day) doses of Virtiva® Plus on stress and cognitive performance over five weeks in stressed individuals. It's randomized and double-blind, meaning neither researchers nor participants know who gets which dose.

What are the potential side effects?

Potential side effects from taking Virtiva® Plus are not specified but will be monitored throughout the trial as part of assessing adverse events related to daily supplementation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 50 and 70 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a history of heart or blood vessel diseases.

Select...

I have a history of neurological disorders like Parkinson's or epilepsy.

Select...

I have or had cancer before.

Select...

I have a history of kidney or liver disease.

Select...

I have a history of metabolic disorders like diabetes.

Select...

I am currently undergoing chemotherapy or radiation treatments.

Select...

I understand the study details and can follow its requirements.

Select...

I do not have gut disorders affecting medication absorption.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre-event, 5 weeks post event

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre-event, 5 weeks post event

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-event, 5 weeks post event for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Abbreviated Profile of Mood States (POMS)

Dysfunctional Attitudes Scale-17 (DAS-17)

Everyday Cognition 12 Scale (ECog-12)

+5 more

Secondary study objectives

4-Part Continuous Performance Test (4PCPT)

Continuous Performance Test

Finger Tapping Test (FTT)

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Low Dose Virtiva PlusExperimental Treatment1 Intervention

One dose (1 capsule) of Virtiva Plus will be consumed twice daily for up to 5 weeks. A single dose contains: 120mg Ginkgo biloba extract (leaf), a minimum of 14.4mg phosphatidylserine, and a minimum of 6mg ginkgo flavonglycosides.

Group II: High Dose Virtiva PlusExperimental Treatment1 Intervention

One dose (1 capsule) of Virtiva Plus will be consumed twice daily for up to 5 weeks. A single dose contains: 240mg Ginkgo biloba extract (leaf), a minimum of 28.8mg phosphatidylserine, and a minimum of 12mg ginkgo flavonglycosides.

0 / 9Eligibility criteria met